BMS and Clovis Collaborate to Test Opdivo, Rubraca Combo Therapy in Ovarian, Other Cancer Types

BMS and Clovis Collaborate to Test Opdivo, Rubraca Combo Therapy in Ovarian, Other Cancer Types
A new clinical collaboration has been established between Bristol-Myers Squibb (BMS) and Clovis Oncology to evaluate the performance of Opdivo (nivolumab) in combination with Rubraca (rucaparib) in a Phase 3 trial for advanced ovarian cancer. Additional clinical trials testing the combination therapy will include patients with triple-negative breast cancer and metastatic prostate cancer. The pivotal Phase 3 trial will evaluate three

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *